United StatesVijay Kumar, who served as the acting director of the FDA's Office of Therapeutic Products, which oversees cell and gene therapies, is resigning from his position. Kumar's departure comes amid significant leadership changes within the FDA, particularly in the Center for Biologics Evaluation and Research (CBER). He was appointed to the role by CBER Director Vinay Prasad, who had previously removed Nicole Verdun from the position. Kumar indicated he made the decision to step down after discussions with agency leadership, stating that they agreed not to renew his temporary assignment.
Bias read (Center): The article presents factual information regarding personnel changes within the FDA without overtly favoring any particular political perspective. It outlines the sequence of events and decisions made by involved parties without using biased language or selectively emphasizing certain viewpoints.
Why these scores (Factual 85 · Objective 90): The article accurately reports on Vijay Kumar's departure from the FDA, citing an email he sent and contextualizing it within the broader leadership changes at the agency. It presents the information neutrally without apparent bias.
